Introduction
Acute respiratory failure (RF), defined as fall in blood oxygen concentration (hypoxaemia) with or without hypercapnia, is one of the most important causes of emergency department presentation in adults. High-flow 'Venturi' masks and low-flow reservoir masks or thin nasal cannulas are the standard forms of conventional oxygen therapy (COT) to treat these patients. However, RF is not often fully compensated with COT and requires greater respiratory support. Traditionally, this was only provided by a ventilator, generating positive intrathoracic pressure (PIP) via endotracheal intubation (EI). Nevertheless, EI carries its own risks, and usually requires complete sedation and admission to a critical care area. Non-invasive ventilation (NIV) is a technique that emerged in the 1980's, that consists of applying positive pressure to conscious patients through different interfaces, it has been shown to be useful in acute RF, reducing the need for EI and decreasing its associated risk of infection, mainly ventilatorassociated pneumonia. 1 Since its introduction, NIV has been extended to different areas of the hospital, the pre-hospital setting and even domiciliary care, while ventilation through EI has remained limited to critical units or the operating theatre. Non-invasive ventilation is indicated to treat RF in a range of different scenarios, including dysfunction of the nervous system, muscles, chest wall, airways, and lung parenchyma, such as acute heart failure (AHF).
Acute respiratory failure in acute heart failure syndromes
Pulmonary oedema is the second most frequent (after pneumonia) acute parenchymal alteration causing RF. Some degree of pulmonary (interstitial/alveolar) oedema may be observed in most of patients with AHF syndromes. 2 Consequently, nearly 90% of AHF patients complain of dyspnoea, 3 but fewer than half present with RF affecting the blood gas analysis, in form of hypoxaemia, hypercapnia, acidosis, or a combination thereof. 4 In relation to the different AHF syndromes, significant RF is primarily seen in acute cardiogenic pulmonary oedema (ACPE), in cardiogenic shock (CS) and in cases associated to other lung alterations.
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Acute cardiogenic pulmonary oedema: The hallmark of this syndrome is a rapid increase in pulmonary capillary hydrostatic pressure and trans-vascular fluid filtration that exceeds the lymphatic interstitial drainage capacity. 6 Respiratory failure occurs when an excess of interstitial and alveoli fluid results in a significant reduction of gas exchange and a concomitant shunt effect. Acute cardiogenic pulmonary oedema is a stressful scenario with progressive RF that may lead to cardiorespiratory collapse in hours, or minutes, unless therapeutic action is taken. Several clinical criteria are required for the diagnosis of ACPE (Table 1) . 7, 8 Initial bedside assessment using the clinical criteria allows the initiation of urgent therapies, but the diagnosis should be confirmed thereafter by additional criteria, more specific for AHF. Key clinical findings are respiratory distress and RF. Other AHF scenarios with interstitial or mild alveolar oedema without significant RF or respiratory distress would not be considered ACPE.
The rate and speed of alveolar fluid filtration, microvascular membrane permeability, alteration in sodium-chloride and water reabsorption, as well as inflammation and individual genetic susceptibility Diagnostic confirmation (at least two of the following)
• Clear signs of pulmonary congestion on chest radiography or CT scan
• Multiple B-lines on lung ultrasound 4 • Elevated pulmonary capillary pressure on catheterization • Increased total lung water on pulse contour and thermodilution analysis system
• Signs of elevated filling pressures on echocardiography 5 • Significant elevation of natriuretic peptides 6 (1) Respiratory distress: Acute increase in the work of breathing (assessed by single inspection), significant tachypnea (RR > 25breaths/min) a , may be with the use of accessory muscles or abdominal paradox (2) Crackles ± wheezes over the lungs, third heart sound b (3) Oxygen saturation on room air by pulse-oximetry (SpO 2 ) <90%.
Arterial blood gases may also show PaO 2 < 60 mmHg, Cardiogenic shock (CS): When CS is secondary to LV failure, acute RF is nearly always present, with concomitant pulmonary oedema and tissue hypoperfusion. In addition to pulmonary oedema, the reduction in lung perfusion produces an increase in pulmonary dead space (some ventilated areas receive less blood), increasing the ventilation-perfusion mismatch. In addition, systemic circulatory failure precipitates metabolic acidosis (lactic acidemia), that increases the compensatory respiratory load, and reduces central venous oxygen content (SvO 2 ) by an augmented arterio-venous difference (greater tissue oxygen extraction). These abnormalities exacerbate the RF in CS.
Other scenarios: Patients with AHF often have concomitant COPD, asthma, pneumonia, large pleural effusion, atelectasis or pulmonary embolism, which may precipitate or aggravate RF. Further, in isolated right ventricular (RV) failure, RF is mainly seen in cases of acute pulmonary thrombo-embolism or decompensated chronic pulmonary hypertension.
Rationale for non-invasive ventilation in acute heart failure
The net effect of PIP is an increase in oxygenation and a decrease in the work of breathing. 11 In the case of ventilatory support, an additional improvement in alveolar ventilation should be expected, with further decreases in the work of breathing and carbon dioxide levels. However, positive pressure changes heart-lung interactions, with haemodynamic and respiratory effects ( Table 2) , including a tendency to reduce cardiac output and blood pressure. Conversely, in AHF patients with elevated preload and afterload, it may increase cardiac output by reducing both pre-and afterload 12, 13 and reducing intrapulmonary shunting. 14 Finally, when there is isolated RV dysfunction, positive pressure may be detrimental as the increase in RV afterload may precipitate or aggravate RV failure. Table 3 shows the features of the most commonly used modalities of NIV in acute settings. The main applications are continuous positive airway pressure (CPAP), non-invasive pressure support ventilation (NIPSV), and more recently, high-flow nasal cannula (HFNC).
Modalities of non-invasive ventilation
Continuous positive airway pressure (CPAP) is the simplest NIV technique and consists of the application of continuous positive pressure into the lungs (Figure 1) . It can be applied without the aid of a ventilator, by using a source of air or oxygen to renew the air through a hermetically sealed mask equipped with positive end expiratory pressure (PEEP) valve, or with the Boussignac system. 15 Non-invasive pressure support ventilation (NIPSV): This modality, the core of NIV, requires a ventilator. It is programmed with two levels of pressure: expiratory pressure (EPAP) or PEEP, and inspiratory pressure (IPAP), which is obtained with pressure support (See Figure  2) . It is also called non-invasive intermittent positive pressure ventilation (NIPPV), or sometimes bilevel or BiPAP. The final result is equivalent to a CPAP mode with inspiratory assistance. This method requires some experience for setting the ventilator to the changing needs of the patient. Adequate synchrony is essential. The respiratory rate is not pre-set and depends exclusively on the patient.
High-flow nasal cannula (HFNC): This system delivers a heated and humidified oxygen-gas mixture (up to 60-80 L/min) that exceeds patients' spontaneous inspiratory demand through a nasal cannula adjusted to the nostrils ( Figure 3 ). There are beneficial actions: a low level of PEEP (<5 cmH 2 O); a washout effect in nasopharyngeal. 16 It should be noted that with an open mouth, the PEEP effect practically disappears. 17 This could be a disadvantage in ACPE patients with severe dyspnoea who generally mouth breath.
Other modalities: See Table 3 for explanations.
Evidence and recommendations for the use of non-invasive ventilation in acute heart failure syndromes
Continuous positive airway pressure and non-invasive pressure support ventilation in acute cardiogenic pulmonary oedema
Acute cardiogenic pulmonary oedema is the second most frequent indication for NIV. 18 The first randomized trials performed at the end of the 1980's using CPAP, showed faster improvement of RF than COT 19, 20 with a reduction in EI rate. 20 The first randomized trial of 26 In addition, the patients in 3-CPO were not hypoxaemic (mean PaO 2 was 100 mmHg in the three arms at study entry), meaning that a clear advantage from NIV in might not be easily shown in patients with mild RF and very low EI rate. The second argument concerned crossover. There was a high crossover rate in 3-CPO (nearly 20% of the patients) mainly due to discomfort (intolerance) in NIV groups, or worsening RF in the COT group (which was significantly higher than in the NIV groups). Finally, although the effect of NIV on mortality after the 3-CPO remains inconclusive, a subsequent meta-analysis including this trial, showed that both modalities reduced the EI rate and still CPAP reduced mortality [relative risk 0.64 (95% CI, 0.44-0.92)], mainly in high-risk patients with acute coronary syndromes. 27 There are no specific trials focused on patients with hypertensive ACPE, but in this case, NIV may be used to improve symptoms. 28 Several studies have shown that the early application of CPAP in the pre-hospital care of patients with ACPE improved RF faster than COT, with a tendency to reduce the EI rate. [29] [30] [31] Because CPAP does not require special training or expensive equipment it can be recommended in this setting. Recent surveys have shown a dramatic expansion in use of NIV in the general population in the last decades, particularly in ACPE, 32 but with a wide variation among centres. 33 Data from 2430 patients who required ventilatory support in the ADHERE registry, supported the use of NIV to avoid EI. 34 The latest ESC guidelines have given NIV a Class IIa recommendation with level of evidence B 35, 36 in patients with respiratory distress (respiratory rate > 25 breaths/min, SpO 2 < 90%). The NICE guidelines in AHF recommended NIV in patients with ACPE with severe dyspnoea and acidemia. 37 Finally, e very recent guidelines from ERC/ ATS recommend NIV, either bilevel NIV or CPAP, for patients with ARF due to ACPE and suggest it in the pre-hospital setting. 38 We recommend that NIV should be used in patients with ACPE, as defined above, in order to reverse RF faster, avoid EI and, with lower evidence, potentially reduce mortality in high risk patients. Continuous positive airway pressure may be the best option in the pre-hospital setting.
High-flow nasal cannula in acute heart failure
In adults, HFNC has recently shown to be effective in the weaning of patients from mechanical ventilation 39, 40 and in hypoxaemic RF from different aetiologies. 41 In AHF the data are scarce, with only one randomized study published this year. This included 128 patients with ACPE, in which HFNC only showed a greater decrease in respiratory rate after 60 min compared to COT. 42 High-flow nasal cannula has been also used in stable Class III heart failure patients 43 and in a short series of AHF patients needing prolonged ventilation support. 44 In some comparative studies HFNC was better tolerated than NIPSV, 45 which anticipates an expansion of the technique. It can be recommended in patients needing prolonged ventilation support, during weaning and in hypoxaemic AHF not tolerating CPAP/NIPSV or failing COT, although further trials are necessary to establish its optimal indications. 
Other modalities in acute heart failure
In a small randomized trial including 36 patients, Proportional Assist Ventilation showed similar results vs. CPAP. 47 In a series of patients with ACPE from Japan, Adapted Servoventilation resulted slightly better than COT. 48 However, this technique showed a potential increase in mortality when was applied to treat sleep apnoea in patients with chronic heart failure and reduced EF 49 and therefore, it was considered Class III in the latest ESC-guidelines. 35 Other modalities 50,51 presented in Table 3 have not been tested in AHF.
Non-invasive ventilation and myocardial infarction
Acute myocardial infarction (AMI) is a frequent cause of ACPE. However, the clinical picture may be confusing as ACPE often is associated with a rise in high-sensitivity troponin, and it may be difficult to know whether ACPE was precipitated by AMI or whether cardiomyocyte injury was the consequence of ACPE. 52 Two old studies suggested that NIPSV could precipitate AMI. The first comparing NIPSV to CPAP was prematurely stopped after recruiting 27 patients due to a higher rate of AMI in the NIPSV group, 53 but the majority of patients already had chest pain on admission, suggesting a recruitment bias rather than an effect of ventilatory therapy. The second study, started in mobile intensive care units in Israel, 54 compared NIPSV to nitrates and showed higher rates of AMI (55 vs. 10%) and EI (80% vs. 20%) in the NIV group. However, patients allocated to the NIV received less intravenous medical therapy and the protocol imposed strict ventilator restrictions, resulting in a very low pressure support (average: 5 cmH 2 O) that could have led to hypoventilation. This may have contributed to the poor results with NIV in this trial, as low tidal volumes may increase alveolar oedema due to the negative intrathoracic pressure precipitated by the patient's inspiratory effort. 55 No other trial has reproduced these results, including randomized trials specifically designed to assess this issue, [56] [57] [58] case-control studies 59 or metaanalyses. In addition, in 3-CPO, NIV was safely used in patients with AMI, who accounted for nearly 50% of the population enrolled, with no differences in the incidence of AMI between groups. 25 However, it should be emphasized that patients with ST segment elevation (STEMI) have not usually been included in the trials. On the other hand, recent data have shown no effect of oxygen therapy in patients with suspected AMI without hypoxaemia. 60 In summary, there is no relationship between use of NIV and risk of AMI, and NIV may be considered in patients with ACPE complicating a Type II AMI or a non-STEMI. Further data are necessary to assess the role of NIV in patients with STEMI.
Non-invasive ventilation in cardiogenic shock
There are no studies analysing NIV in this clinical situation. Traditionally, patients with CS have not been candidates for the 
technique. Although RF is always present in these patients, frequently altered mental status does not ensure correct spontaneous breathing and preservation of the upper airway, two conditions necessary for the appropriate use of NIV. Furthermore, PIP tends to decrease blood pressure, aggravating hypoperfusion. However, in the 'Cardshock study', 61 NIV was used in nearly 13% of the patients with early or non-severe CS, after correction of hypotension, avoiding EI in the majority. 62 Therefore, although the use of NIV remains limited in hypotensive patients, it may be cautiously considered in selected CS patients without severe haemodynamic instability. The potential use of HFNC in this context should be assessed.
Non-invasive ventilation in other acute heart failure scenarios
There are no randomized studies specifically analysing the effect of NIV in patients with isolated RV failure. As a general rule, mechanical ventilation should be avoided in these patients. 63 However, in cases with RF of mixed origin (COPD with pulmonary oedema), NIV may be especially useful because it may benefit both underlying conditions. 64 
Continuous positive airway pressure or non-invasive pressure support ventilation
Although theoretically NIPSV should be superior to CPAP because it provides an inspiratory help, no trials or meta-analyses have demonstrated a clear advantage of one technique over the other for important outcomes in patients with AHF, but those treated with NIPSV have shown faster improvement in several physiological variables in some trials. 53, [65] [66] [67] In case-series of patients with ACPE, NIPSV was most clearly effective in those with hypercapnia. 21, 68 Consequently, either technique can be used as a first line treatment in ACPE, but it seems reasonable to prefer NIPSV in patients with severe hypercapnia, although little evidence supports this recommendation.
Practical aspects Equipment Interfaces
The interface is the component that most defines NIV, and it is crucial for treatment success. In order to avoid leaks, a tight seal between the patient's face and the device is essential, but often difficult to obtain. There are different types of interfaces (see Figure 3) .
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Ventilators
There are three types of ventilators: portable (designed specifically for NIV), transport, and ICU-ventilators. All of them have particular settings for CPAP and NIPSV. Portable NIV ventilators are less expensive have higher mobility, do not need an air flow source and seem to allow better synchrony than ICU and transport ventilators. 70 A wide range of ventilators is currently on the market, from the simplest (only pressure is modifiable) to the latest generation high-tech ventilators (display monitoring, alarm setting, leakage compensation, different triggers, cycling and flow ramp control, etc.). The most important attribute of the equipment is leakage compensation through an increase of air flow (up to 120-180 L/min).
Complements
Skin protectors are recommended. Heat humidification or heat and moisture exchangers are recommended because they may facilitate NIV. 71 Nebulizers can be used safely without interrupting NIV therapy. Sedation: Mild sedation decreases respiratory rate and intolerance 72, 73 and is used nearly 20% of the patients treated with NIV. 74 However, sedation may cause adverse events (hypoventilation, hypotension and also, vomiting or aspiration with opioids) and should be used only in patients who remain uncooperative or who show poor synchrony with the ventilator, and then only after nonpharmacological approaches have been tried 75 (e.g. changing the interface, tuning the ventilator, reassuring the patient, etc.). Experienced staff and appropriate monitoring (e.g. targeting a sedation scale or respiratory rate) is essential. 76 Minimal intermittent doses of a single drug may be preferable to continuous infusions or combinations of different agents. 74, 75 Morphine (boluses of 2-4 mg)
is the most used single drug in this setting, 72 although recent data raised safety concern of its use in AHF. 77 Other opioids, propofol, midazolam, and more recently dexmedetomidine, which is an a2-adrenergic receptor agonist with less central respiratory depression, have been used in this context.
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Starting non-invasive ventilation Before starting the technique, the contraindications for NIV should be considered (Table 4) . Empathic communication between nurses/ physicians and the patient is essential, with clear instructions about what to expect and frequent encouragement thereafter. By fitting the mask manually at the onset, patients gain confidence with the technique, and it later may be secured fixed with strips in a similar manner.
Device settings
For NIPSV, it is recommendable to start with low levels of PEEP (3-4 cmH 2 O) and pressure support of 7-8 cmH 2 O, increasing it progressively according to patients' adaptation and response. Target tidal volumes are 4-7 mL/kg (often lower in COPD patients). With 
Monitoring non-invasive ventilation
To ensure the success of NIV, close monitoring is necessary (Table 5) , especially respiratory rate (patient's effort), oxygen saturation (F I O 2 may need to be adjusted), and pH/PaCO 2 (to assess efficacy). Visualization of flow and pressure waveforms on a continuous display is recommended 78 ( Figure 4) . In addition to continuous observation, general reassessment is recommended at 60 and/or 90-120 min, with special attention paid to risk factors for failure. 79 The key issue is optimal synchronization between the patient's spontaneous breathing and the ventilator. [80] [81] [82] Air leakage is often involved in cases of asynchrony, which may be reduced by one or more of adjusting the mask, shortening inspiration time, changing 
When to stop
Non-invasive ventilation is usually stopped when a satisfactory recovery has been achieved (usually 2-5 h in ACPE) or conversely, if there are signs of NIV failure, requiring EI ( 
Conclusions
In AHF syndromes NIV should be used in patients with ACPE. It may be considered in other AHF patients with RF associated with lung disease and in some cases of CS, after stabilizing the blood pressure.
Continuous positive airway pressure is a simpler technique that is recommended as first line therapy in these scenarios, particularly in the pre-hospital setting or in less well-equipped areas. Non-invasive pressure support ventilation is equally effective in ACPE and may be preferable, by experienced teams, in patients with significant hypercapnia. High-flow nasal cannula may be an alternative, especially in patients with AHF requiring prolonged NIV, but is a well-tolerated NIV technique with wider potential indications.
The overall approach for the use of NIV in AHF, as a complement to recent ESC consensus papers and guidelines, 35, [84] [85] [86] is shown in Take Continuous positive airway pressure may be preferred in pre-hospital and low equipped areas, whereas non-invasive pressure support ventilation may be chosen by experienced teams, in patients with significant hypercapnia or COPD. Proportional assist ventilation, adaptive servoventilation, and HFNC have also been used in some trials as first line therapy in ACPE. COPD, chronic obstructive pulmonary disease; HFNC, high-flow nasal cannula; EI, endotracheal intubation; COT, conventional oxygen therapy; ACPE, acute cardiogenic pulmonary oedema.
